UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2571-2571

2021

Volltextzugriff (PDF)

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

Journal of clinical oncology, 2010-08, Vol.28 (23), p.3701-3708

2010

Volltextzugriff (PDF)

Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study

Gynecologic oncology, 2024-07, Vol.186, p.191-198

2024

Volltextzugriff (PDF)

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

Journal for Immunotherapy of Cancer, 2017-06, Vol.5 (1), p.50-50, Article 50

2017

Volltextzugriff (PDF)

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Cancer chemotherapy and pharmacology, 2015-01, Vol.75 (1), p.183-189

2015

Volltextzugriff (PDF)

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer

Investigational new drugs, 2013-06, Vol.31 (3), p.669-676

2013

Volltextzugriff (PDF)

A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis

Pediatric blood & cancer, 2017-05, Vol.64 (5), p.np-n/a

2017

Volltextzugriff (PDF)

Blockade of interleukin‐6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

British journal of haematology, 2011-03, Vol.152 (5), p.579-592

2011

Volltextzugriff (PDF)

Abstract 5652: Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5652-5652

2017

Volltextzugriff (PDF)

Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM)

Journal of clinical oncology, 2017-03, Vol.35 (7_suppl), p.136-136

2017

Volltextzugriff (PDF)

Change in worksite smoking behavior following cancer risk feedback: a pilot study

American journal of health behavior, 2005-05, Vol.29 (3), p.215-227

2005

Volltextzugriff (PDF)

Implementation of a comprehensive cancer control program at the worksite: year one summary report

Journal of occupational and environmental medicine, 2002-05, Vol.44 (5), p.398-406

2002

Volltextzugriff (PDF)

Abstract CT205: A phase I dose-escalation study of trametinib (T) in combination with continuous or intermittent GSK2126458 (GSK458) in patients (pts) with advanced solid tumors

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.CT205-CT205

2014

Volltextzugriff (PDF)

Eastern Cooperative Oncology Group Phase II Trial (E4296) of Oral 5-Fluorouracil and Eniluracil as a 28-Day Regimen in Metastatic Colorectal Cancer

Clinical colorectal cancer, 2002-05, Vol.2 (1), p.43-50

2002

Volltextzugriff (PDF)

CNTO328 (Anti-IL-6 mAb) Treatment Is Associated with An Increase in Hemoglobin (Hb) and Decrease in Hepcidin Levels in Renal Cell Carcinoma (RCC)

Blood, 2009-11, Vol.114 (22), p.4045-4045

2009

Volltextzugriff (PDF)

A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Blood, 2011-11, Vol.118 (21), p.3971-3971

2011

Volltextzugriff (PDF)

Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Blood, 2011-11, Vol.118 (21), p.3959-3959

2011

Volltextzugriff (PDF)

Inhibition of Interleukin-6 Signaling with CNTO 328 Sensitizes Plasma Cell Dyscrasias to the Effects of Melphalan in Association with Suppression of Signaling through Protein Kinase B/Akt

Blood, 2009-11, Vol.114 (22), p.1836-1836

2009

Volltextzugriff (PDF)

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31 st Annual Meeting of the Society for Immunotherapy of Cancer, 2016

Journal for immunotherapy of cancer, 2017, Vol.5, p.50

2017

Volltextzugriff (PDF)

CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman's Disease: Preliminary Results of a Phase I Study

Blood, 2008-11, Vol.112 (11), p.1008-1008

2008

Volltextzugriff (PDF)

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016

Journal for immunotherapy of cancer, 2016-11, Vol.4 (S1), p.1-106, Article 82

2016

Volltextzugriff (PDF)

A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Blood, 2008-11, Vol.112 (11), p.1009-1009

2008

Volltextzugriff (PDF)

Psychological issues related to the use of spiral CT for lung cancer early detection

Lung cancer (Amsterdam, Netherlands), 2003-03, Vol.39 (3), p.315-325

2003

Volltextzugriff (PDF)

Accuracy of cancer-risk assessment in primary care practice

Journal of cancer education, 2001, Vol.16 (4), p.193-198

2001

Volltextzugriff (PDF)

Feasibility of Assessing Quality in Medical Oncology Practices

Cancer practice, 2001-09, Vol.9 (5), p.231-235

2001

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(42)
Tagungsberichte
(3)

Sprache

Englisch
(45)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Humans
(17)
Life Sciences & Biomedicine
(17)
Middle Aged
(13)
Female
(12)
Male
(12)
Adult
(9)
Aged
(9)
Oncology
(9)
Magnetic Resonance Imaging
(7)
Biological And Medical Sciences
(6)
Medical Sciences
(6)
Cancer
(5)
Aged, 80 And Over
(4)
Antineoplastic Agents - Adverse Effects
(4)
Chemotherapy
(4)
Poster Presentation
(4)
Radiology, Nuclear Medicine & Medical Imaging
(4)
Tumors
(4)
Antineoplastic Agents - Therapeutic Use
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203)

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer

A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis

Blockade of interleukin‐6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

Abstract 5652: Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanoma

Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM)

Change in worksite smoking behavior following cancer risk feedback: a pilot study

Implementation of a comprehensive cancer control program at the worksite: year one summary report

Abstract CT205: A phase I dose-escalation study of trametinib (T) in combination with continuous or intermittent GSK2126458 (GSK458) in patients (pts) with advanced solid tumors

Eastern Cooperative Oncology Group Phase II Trial (E4296) of Oral 5-Fluorouracil and Eniluracil as a 28-Day Regimen in Metastatic Colorectal Cancer

CNTO328 (Anti-IL-6 mAb) Treatment Is Associated with An Increase in Hemoglobin (Hb) and Decrease in Hepcidin Levels in Renal Cell Carcinoma (RCC)

A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Inhibition of Interleukin-6 Signaling with CNTO 328 Sensitizes Plasma Cell Dyscrasias to the Effects of Melphalan in Association with Suppression of Signaling through Protein Kinase B/Akt

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31 st Annual Meeting of the Society for Immunotherapy of Cancer, 2016

CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman's Disease: Preliminary Results of a Phase I Study

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016

A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Psychological issues related to the use of spiral CT for lung cancer early detection

Accuracy of cancer-risk assessment in primary care practice

Feasibility of Assessing Quality in Medical Oncology Practices

Suchergebnisse filtern